- Successfully completed stage 1 of 2 audits with TÜV America;
- Received approval for approximately $500K in non-dilutive funding through the sale of New Jersey tax losses.
Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate
Biotech columnist Adam Feuerstein answers readers' questions about health care.
CorMedix (CRMD) shares are rising after the company said that the FDA gave positive feedback for its catheter lock solution for oncology patients.